GH Research (GHRS) Total Current Liabilities (2021 - 2026)
GH Research (GHRS) posted quarterly Total Current Liabilities of $8.4 million for Q4 2025, down 6.4% year-over-year from $9.0 million in Q4 2024, and down 19.49% quarter-over-quarter from $10.4 million in Q3 2025.
GH Research (GHRS) Total Current Liabilities (2021 - 2026) Analysis & Trends
GH Research's Total Current Liabilities history runs 5 years deep, the most recent figure standing at $8.4 million for Q4 2025.
- In Q4 2025, Total Current Liabilities fell 6.4% year-over-year to $8.4 million; the TTM figure through Dec 2025 stood at $8.4 million (down 6.4% YoY), while the FY2025 annual figure was $8.4 million, down 6.4% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $8.4 million, down from $10.4 million in the prior quarter.
- The five-year high for Total Current Liabilities was $10.4 million in Q3 2025, with the low at $2.0 million in Q3 2021.
- The 5-year median for Total Current Liabilities is $6.7 million (2023), against an average of $6.6 million.
- The sharpest annual moves came in 2023 and 2025: Total Current Liabilities jumped 111.86% in 2023, then decreased 6.4% in 2025.
- GH Research's Total Current Liabilities stood at $3.4 million in 2021, then soared by 34.42% to $4.5 million in 2022, then jumped by 47.4% to $6.7 million in 2023, then soared by 33.61% to $9.0 million in 2024, then slipped by 6.4% to $8.4 million in 2025.
- Business Quant data shows GHRS's Total Current Liabilities at $8.4 million in Q4 2025, $10.4 million in Q3 2025, and $10.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | 12.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.85 Mn |
| Dec 31, 2025 | 8.38 Mn |
| Sep 30, 2025 | 10.41 Mn |
| Jun 30, 2025 | 9.97 Mn |
| Mar 31, 2025 | 9.92 Mn |
| Dec 31, 2024 | 8.95 Mn |
| Sep 30, 2024 | 9.79 Mn |
| Jun 30, 2024 | 7.80 Mn |
| Mar 31, 2024 | 7.28 Mn |
| Dec 31, 2023 | 6.70 Mn |
| Sep 30, 2023 | 6.13 Mn |
| Jun 30, 2023 | 6.56 Mn |
| Mar 31, 2023 | 6.64 Mn |
| Dec 31, 2022 | 4.55 Mn |
| Sep 30, 2022 | 3.39 Mn |
| Jun 30, 2022 | 3.10 Mn |
| Mar 31, 2022 | 4.07 Mn |
| Dec 31, 2021 | 3.38 Mn |
| Sep 30, 2021 | 2.03 Mn |